51
|
Kawaguchi Y, Hasegawa K, Tzeng CWD, Mizuno T, Arita J, Sakamoto Y, Chun YS, Aloia TA, Kokudo N, Vauthey JN. Performance of a modified three-level classification in stratifying open liver resection procedures in terms of complexity and postoperative morbidity. Br J Surg 2019; 107:258-267. [PMID: 31603540 DOI: 10.1002/bjs.11351] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 08/05/2019] [Accepted: 08/06/2019] [Indexed: 01/05/2023]
Abstract
BACKGROUND Traditional classifications for open liver resection are not always associated with surgical complexity and postoperative morbidity. The aim of this study was to test whether a three-level classification for stratifying surgical complexity based on surgical and postoperative outcomes, originally devised for laparoscopic liver resection, is superior to classifications based on a previously reported survey for stratifying surgical complexity of open liver resections, minor/major nomenclature or number of resected segments. METHODS Patients undergoing a first open liver resection without simultaneous procedures at MD Anderson Cancer Center (Houston cohort) or the University of Tokyo (Tokyo cohort) were studied. Surgical and postoperative outcomes were compared among three grades: I (wedge resection for anterolateral or posterosuperior segment and left lateral sectionectomy); II (anterolateral segmentectomy and left hepatectomy); III (posterosuperior segmentectomy, right posterior sectionectomy, right hepatectomy, central hepatectomy and extended left/right hepatectomy). RESULTS In both the Houston (1878 patients) and Tokyo (1202) cohorts, duration of operation, estimated blood loss and comprehensive complication index score differed between the three grades (all P < 0·050) and increased in stepwise fashion from grades I to III (all P < 0·001). Left hepatectomy was associated with better surgical and postoperative outcomes than right hepatectomy, extended right hepatectomy and right posterior sectionectomy, although these four procedures were categorized as being of medium complexity in the survey-based classification. Surgical outcomes of minor open liver resections also differed between the three grades (all P < 0·050). For duration of operation and blood loss, the area under the curve was higher for the three-level classification than for the minor/major or segment-based classification. CONCLUSION The three-level classification may be useful in studies analysing open liver resection at Western and Eastern centres.
Collapse
Affiliation(s)
- Y Kawaguchi
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - K Hasegawa
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - C-W D Tzeng
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T Mizuno
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - J Arita
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Y Sakamoto
- Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - Y S Chun
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T A Aloia
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - N Kokudo
- National Centre for Global Health and Medicine, Tokyo, Japan
| | - J-N Vauthey
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
52
|
Mizuno T, Konno H, Kojima H, Isaka M, Ohde Y. P1.17-12 Osteogenic and Brain Metastases After Resection of NSCLC: Implications for the Use of FDG-PET and Brain MRI in Postoperative Surveillance. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
53
|
Konno H, Isaka M, Mizuno T, Kojima H, Ohde Y. P1.17-36 Analyses of Segmental and Intrapulmonary Lymph Node Metastases of Small-Sized Peripheral Solid Predominant Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
54
|
Mizuno T, Tomita N, Uchiyama K, Sugie C, Imai M, Ayakawa S, Niwa M, Matsui T, Otsuka S, Manabe Y, Nomura K, Kondo T, Kosaki K, Akifumi M, Miyamoto A, Takemoto S, Yasui T, Shibamoto Y. Impact of Early Salvage Radiotherapy in Patients with Biochemical Recurrence after Radical Prostatectomy: Results of a Multi-institutional Retrospective Study. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
55
|
Otsuka S, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Watanabe N, Shimoyama Y, Nagino M. Benign hilar bile duct strictures resected as perihilar cholangiocarcinoma. Br J Surg 2019; 106:1504-1511. [PMID: 31386198 DOI: 10.1002/bjs.11257] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 05/07/2019] [Accepted: 05/10/2019] [Indexed: 02/06/2023]
Abstract
BACKGROUND Differentiation between perihilar cholangiocarcinoma (PHCC) and benign strictures is frequently difficult. The aim of this study was to investigate the incidence and long-term outcome of patients with tumours resected because of suspicion of PHCC, which ultimately turned out to be benign (malignancy masquerade). METHODS Patients who underwent surgical resection with a diagnosis of PHCC between 2001 and 2016 were reviewed retrospectively. RESULTS Among 707 consecutive patients, 685 had PHCC and the remaining 22 (3·1 per cent) had benign biliary stricture. All patients with benign disease underwent major hepatectomy, with no deaths. Preoperative histological assessment using bile duct biopsy or aspiration cytology had a high specificity (90 per cent), low sensitivity (62 per cent) and unsatisfactory accuracy (63 per cent). Despite the increasing use of histological assessment, the incidence of benign strictures resected did not decrease over time, being 0·9 per cent in 2001-2004, 4·0 per cent in 2005-2008, 3·8 per cent in 2009-2012 and 2·9 per cent in 2013-2016. The final pathology of benign strictures included IgG4-related sclerosing cholangitis (9 patients), hepatolithiasis (4), granulomatous cholangitis (3), non-specific chronic cholangitis (3), benign strictures after cholecystectomy (2), and a benign stricture possibly caused by parasitic infection (1). The 10-year overall survival rate for the 22 patients with benign stricture was 87 per cent, without recurrence of biliary stricture. CONCLUSION The incidence of benign strictures resected as PHCC as a proportion of all resections was relatively low, at 3·1 per cent. Currently, unnecessary surgery for suspected PHCC is unavoidable.
Collapse
Affiliation(s)
- S Otsuka
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.,Department of Pathology and Clinical Laboratories, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Yokoyama
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Igami
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Mizuno
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - J Yamaguchi
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Onoe
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Watanabe
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Shimoyama
- Department of Pathology and Clinical Laboratories, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
56
|
Hwang CC, Igase M, Okuda M, Coffey M, Noguchi S, Mizuno T. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines. Biochem Biophys Res Commun 2019; 517:233-237. [PMID: 31345575 DOI: 10.1016/j.bbrc.2019.07.050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2019] [Accepted: 07/17/2019] [Indexed: 12/12/2022]
Abstract
Although reovirus has reached phase II and III clinical trials in human cancers, the exact mechanism of reovirus oncolysis is still not completely understood. Previously, we have shown that canine mast cell tumor (MCT) cell lines were highly susceptible to reovirus, as compared with other kinds of canine cancer cell lines. In this study, we showed that reovirus infection not only led to the dephosphorylation but also downregulation of c-kit in four canine MCT cell lines, where c-kit activation is required for proliferation. Consistent with c-kit dysregulation, downstream signaling of c-kit, the level of Ras-GTP and phosphorylation of all the downstream effectors of Ras (Raf, MEK, and ERK) and Akt decreased in all the cell lines after reovirus infection, except for Akt in one of cell lines. Pro-apoptotic and anti-apoptotic proteins such as Bim, Bad and Mcl-1 were also altered by reovirus infection in these cell lines. In short, reovirus infection degraded c-kit in all the canine MCT cell lines, leading to the downregulation of downstream signaling of c-kit, which may relate to the cell death induced by reovirus.
Collapse
Affiliation(s)
- Chung Chew Hwang
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Masaya Igase
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Masaru Okuda
- Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Matt Coffey
- Oncolytics Biotech Inc, Calgary, Alberta, Canada
| | - Shunsuke Noguchi
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Takuya Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan.
| |
Collapse
|
57
|
Mizuno T, Ebata T, Nagino M. Author response to comment on: Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. Br J Surg 2019; 106:1101-1102. [PMID: 31260587 DOI: 10.1002/bjs.11237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 04/18/2019] [Indexed: 11/11/2022]
Affiliation(s)
- T Mizuno
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
58
|
Seguchi O, Fujita T, Kumai Y, Kuroda K, Nakajima S, Watanabe T, Yanase M, Matsumoto Y, Fukushima S, Tsukiya T, Mizuno T, Katagiri N, Kakuta Y, Takewa Y, Hamasaki T, Yamamoto H, Tatsumi E, Kobayashi J, Fukushima N. Novel Extracorporeal Continuous-Flow Ventricular Assist System for Patients with Advanced Heart Failure. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
59
|
Mizuno T, Eura Y, Kokame K, Tsukiya T, Takewa Y, Tatsumi E. Cleavage and Re-Supply of von Willebrand Factor in Continuous Flow Blood Pump. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.1093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
60
|
Mizuno T, Fujiwara T, Kuroki H, Oishi K, Takeshita M, Yashima M, Oi K, Arai H. What Should Be Done for Improving the Outcomes of Salvage from Cardiogenic Shock on ECMO Support? J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.1163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
61
|
Sugita S, Honda R, Morota T, Kameda S, Sawada H, Tatsumi E, Yamada M, Honda C, Yokota Y, Kouyama T, Sakatani N, Ogawa K, Suzuki H, Okada T, Namiki N, Tanaka S, Iijima Y, Yoshioka K, Hayakawa M, Cho Y, Matsuoka M, Hirata N, Hirata N, Miyamoto H, Domingue D, Hirabayashi M, Nakamura T, Hiroi T, Michikami T, Michel P, Ballouz RL, Barnouin OS, Ernst CM, Schröder SE, Kikuchi H, Hemmi R, Komatsu G, Fukuhara T, Taguchi M, Arai T, Senshu H, Demura H, Ogawa Y, Shimaki Y, Sekiguchi T, Müller TG, Hagermann A, Mizuno T, Noda H, Matsumoto K, Yamada R, Ishihara Y, Ikeda H, Araki H, Yamamoto K, Abe S, Yoshida F, Higuchi A, Sasaki S, Oshigami S, Tsuruta S, Asari K, Tazawa S, Shizugami M, Kimura J, Otsubo T, Yabuta H, Hasegawa S, Ishiguro M, Tachibana S, Palmer E, Gaskell R, Le Corre L, Jaumann R, Otto K, Schmitz N, Abell PA, Barucci MA, Zolensky ME, Vilas F, Thuillet F, Sugimoto C, Takaki N, Suzuki Y, Kamiyoshihara H, Okada M, Nagata K, Fujimoto M, Yoshikawa M, Yamamoto Y, Shirai K, Noguchi R, Ogawa N, Terui F, Kikuchi S, Yamaguchi T, Oki Y, Takao Y, Takeuchi H, Ono G, Mimasu Y, Yoshikawa K, Takahashi T, Takei Y, Fujii A, Hirose C, Nakazawa S, Hosoda S, Mori O, Shimada T, Soldini S, Iwata T, Abe M, Yano H, Tsukizaki R, Ozaki M, Nishiyama K, Saiki T, Watanabe S, Tsuda Y. The geomorphology, color, and thermal properties of Ryugu: Implications for parent-body processes. Science 2019; 364:252. [PMID: 30890587 DOI: 10.1126/science.aaw0422] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 03/12/2019] [Indexed: 11/02/2022]
Abstract
The near-Earth carbonaceous asteroid 162173 Ryugu is thought to have been produced from a parent body that contained water ice and organic molecules. The Hayabusa2 spacecraft has obtained global multicolor images of Ryugu. Geomorphological features present include a circum-equatorial ridge, east-west dichotomy, high boulder abundances across the entire surface, and impact craters. Age estimates from the craters indicate a resurfacing age of [Formula: see text] years for the top 1-meter layer. Ryugu is among the darkest known bodies in the Solar System. The high abundance and spectral properties of boulders are consistent with moderately dehydrated materials, analogous to thermally metamorphosed meteorites found on Earth. The general uniformity in color across Ryugu's surface supports partial dehydration due to internal heating of the asteroid's parent body.
Collapse
Affiliation(s)
- S Sugita
- The University of Tokyo, Tokyo 113-0033, Japan. .,Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - R Honda
- Kochi University, Kochi 780-8520, Japan
| | - T Morota
- Nagoya University, Nagoya 464-8601, Japan
| | - S Kameda
- Rikkyo University, Tokyo 171-8501, Japan
| | - H Sawada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - E Tatsumi
- The University of Tokyo, Tokyo 113-0033, Japan
| | - M Yamada
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - C Honda
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Yokota
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Kochi University, Kochi 780-8520, Japan
| | - T Kouyama
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064 Japan
| | - N Sakatani
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Ogawa
- Kobe University, Kobe 657-8501, Japan
| | - H Suzuki
- Meiji University, Kawasaki 214-8571, Japan
| | - T Okada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,The University of Tokyo, Tokyo 113-0033, Japan
| | - N Namiki
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - S Tanaka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - Y Iijima
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Yoshioka
- The University of Tokyo, Tokyo 113-0033, Japan
| | - M Hayakawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Cho
- The University of Tokyo, Tokyo 113-0033, Japan
| | - M Matsuoka
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Hirata
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - N Hirata
- Kobe University, Kobe 657-8501, Japan
| | - H Miyamoto
- The University of Tokyo, Tokyo 113-0033, Japan
| | - D Domingue
- Planetary Science Institute, Tucson, AZ 85719, USA
| | | | - T Nakamura
- Tohoku University, Sendai 980-8578, Japan
| | - T Hiroi
- Brown University, Providence, RI 02912, USA
| | - T Michikami
- Kindai University, Higashi-Hiroshima 739-2116, Japan
| | - P Michel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre National de le Recherche Scientifique (CNRS), Laboratoire Lagrange, 06304 Nice, France
| | - R-L Ballouz
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,University of Arizona, Tucson, AZ 85705, USA
| | - O S Barnouin
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - C M Ernst
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA
| | - S E Schröder
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - H Kikuchi
- The University of Tokyo, Tokyo 113-0033, Japan
| | - R Hemmi
- The University of Tokyo, Tokyo 113-0033, Japan
| | - G Komatsu
- International Research School of Planetary Sciences, Università d'Annunzio, 65127 Pescara, Italy.,Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - T Fukuhara
- Rikkyo University, Tokyo 171-8501, Japan
| | - M Taguchi
- Rikkyo University, Tokyo 171-8501, Japan
| | - T Arai
- Ashikaga University, Ashikaga 326-8558, Japan
| | - H Senshu
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - H Demura
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Ogawa
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Shimaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Sekiguchi
- Hokkaido University of Education, Asahikawa 070-8621, Japan
| | - T G Müller
- Max-Planck-Institut für Extraterrestrische Physik, 85748 Garching, Germany
| | - A Hagermann
- University of Stirling, FK9 4LA, Scotland, UK
| | - T Mizuno
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Noda
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - K Matsumoto
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - R Yamada
- University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - Y Ishihara
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Ikeda
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - H Araki
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - K Yamamoto
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Abe
- Nihon University, Funabashi 274-8501, Japan
| | - F Yoshida
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - A Higuchi
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Sasaki
- Osaka University, Toyonaka 560-0043, Japan
| | - S Oshigami
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Tsuruta
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - K Asari
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - S Tazawa
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - M Shizugami
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan
| | - J Kimura
- Osaka University, Toyonaka 560-0043, Japan
| | - T Otsubo
- Hitotsubashi University, Tokyo 186-8601, Japan
| | - H Yabuta
- Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - S Hasegawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Ishiguro
- Seoul National University, Seoul 08826, Korea
| | - S Tachibana
- The University of Tokyo, Tokyo 113-0033, Japan
| | - E Palmer
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - R Gaskell
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - L Le Corre
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - R Jaumann
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - K Otto
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - N Schmitz
- German Aerospace Center (DLR), Institute of Planetary Research, 12489 Berlin, Germany
| | - P A Abell
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - M A Barucci
- Laboratoire d'Etudes Spatiales et d'Instrumentation en Astrophysique (LESIA)-Observatoire de Paris, Paris Sciences et Lettres (PSL), Centre National de le Recherche Scientifique (CNRS), Sorbonne Université, Université Paris-Diderot, 92195 Meudon Principal Cedex, France
| | - M E Zolensky
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - F Vilas
- Planetary Science Institute, Tucson, AZ 85719, USA
| | - F Thuillet
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre National de le Recherche Scientifique (CNRS), Laboratoire Lagrange, 06304 Nice, France
| | - C Sugimoto
- The University of Tokyo, Tokyo 113-0033, Japan
| | - N Takaki
- The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Suzuki
- The University of Tokyo, Tokyo 113-0033, Japan
| | | | - M Okada
- The University of Tokyo, Tokyo 113-0033, Japan
| | - K Nagata
- National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064 Japan
| | - M Fujimoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Yoshikawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - Y Yamamoto
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - K Shirai
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - R Noguchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Ogawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - F Terui
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Kikuchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Yamaguchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Oki
- The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Takao
- The University of Tokyo, Tokyo 113-0033, Japan
| | - H Takeuchi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - G Ono
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - Y Mimasu
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Yoshikawa
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - T Takahashi
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Takei
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - A Fujii
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - C Hirose
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - S Nakazawa
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Hosoda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - O Mori
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Shimada
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Soldini
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Iwata
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - M Abe
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - H Yano
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - R Tsukizaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Ozaki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| | - K Nishiyama
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Saiki
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Watanabe
- Nagoya University, Nagoya 464-8601, Japan.,Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Tsuda
- Institute of Space and Astronautical Science (ISAS), Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,SOKENDAI (The Graduate University for Advanced Studies), Hayama 240-0193, Japan
| |
Collapse
|
62
|
Otsuka S, Ebata T, Yokoyama Y, Mizuno T, Tsukahara T, Shimoyama Y, Ando M, Nagino M. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma. Br J Surg 2019; 106:774-782. [DOI: 10.1002/bjs.11125] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Revised: 11/27/2018] [Accepted: 12/20/2018] [Indexed: 12/14/2022]
Abstract
Abstract
Background
Little is known about the effect of additional resection for a frozen-section-positive distal bile duct margin (DM) in perihilar cholangiocarcinoma.
Methods
Patients who underwent surgical resection for perihilar cholangiocarcinoma between 2001 and 2015 were analysed retrospectively, focusing on the DM.
Results
Of 558 consecutive patients who underwent frozen-section examination for a DM, 74 (13·3 per cent) had a frozen-section-positive DM with invasive cancer or carcinoma in situ. Eventually, 53 patients underwent additional resection (bile duct resection in 44 and pancreatoduodenectomy in 9), whereas the remaining 21 patients did not. Ultimately, R0 resection was achieved in 30 of the 53 patients (57 per cent). No patient who underwent additional resection died from surgical complications. The 44 patients with additional bile duct resection had a 5-year overall survival rate of 31 per cent. Overall survival of the nine patients who had pancreatoduodenectomy was better, with a 10-year rate of 67 per cent. Survival of the 21 patients without additional resection was dismal: all died within 5 years. Multivariable analyses identified nodal status and additional resection as independent prognostic factors (lymph node metastasis: hazard ratio (HR) 2·26, 95 per cent c.i. 1·26 to 4·07; bile duct resection versus no additional resection: HR 0·32, 0·17 to 0·60; pancreatoduodenectomy versus no additional resection: HR 0·08, 0·02 to 0·29).
Conclusion
Additional resection for frozen-section-positive DM in perihilar cholangiocarcinoma frequently yields R0 margins. It offers a better chance of long-term survival, and thus should be performed in carefully selected patients.
Collapse
Affiliation(s)
- S Otsuka
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Department of Pathology and Clinical Laboratories, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Yokoyama
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Mizuno
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Tsukahara
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Department of Pathology and Clinical Laboratories, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Shimoyama
- Department of Pathology and Clinical Laboratories, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Ando
- Data Coordinating Centre, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
63
|
Igase M, Shousu K, Fujiki N, Sakurai M, Bonkobara M, Hwang CC, Coffey M, Noguchi S, Nemoto Y, Mizuno T. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells. Vet Comp Oncol 2019; 17:184-193. [PMID: 30761736 DOI: 10.1111/vco.12468] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 02/09/2019] [Accepted: 02/11/2019] [Indexed: 12/13/2022]
Abstract
Canine histiocytic sarcoma is an aggressive, fatal neoplastic disease with a poor prognosis. Lomustine is generally accepted as the first-line systemic therapy, although this compound does not provide complete regression. Therefore, research into a novel approach against canine histiocytic sarcoma is needed. However, anti-tumour effects of oncolytic therapy using reovirus against histiocytic sarcoma are unknown. Here, we showed that reovirus has oncolytic activity in canine histiocytic sarcoma cell lines in vitro and in vivo. We found that reovirus can replicate and induce caspase-dependent apoptosis in canine histiocytic sarcoma cell lines. A single intra-tumoural injection of reovirus completely suppressed the growth of subcutaneously grafted tumours in NOD/SCID mice. Additionally, we demonstrated that susceptibility to reovirus-induced cell death was attributable to the extent of expression of type I interferons induced by reovirus infection in vitro. In conclusion, oncolytic reovirus appears to be an effective treatment option for histiocytic sarcoma, and therefore warrants further investigation in early clinical trials.
Collapse
Affiliation(s)
- Masaya Igase
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - Kazuha Shousu
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Noriyuki Fujiki
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Masashi Sakurai
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Makoto Bonkobara
- Laboratory of Veterinary Clinical Pathology, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan
| | - Chung C Hwang
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - Matt Coffey
- Oncolytics Biotech Inc., Calgary, Alberta, Canada
| | - Shunsuke Noguchi
- Laboratory of Veterinary Radiology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan
| | - Yuki Nemoto
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Takuya Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| |
Collapse
|
64
|
Mizuno T, Matsumoto H, Mita K, Kogauchi S, Kiyono Y, Kosaka H, Omata N. Psychosis is an extension of mood swings from the perspective of neuronal plasticity impairments. Med Hypotheses 2019; 124:37-39. [PMID: 30798913 DOI: 10.1016/j.mehy.2019.02.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 01/04/2019] [Accepted: 02/01/2019] [Indexed: 12/27/2022]
Abstract
We previously hypothesized that depressive and manic states may be consecutive presentations of the same underlying neuronal plasticity, and that moderate impairments in neuronal plasticity cause depressive states while further impairment to neuronal plasticity causes manic states. Psychopathological or biological relationships between bipolar disorder and schizophrenia have also been revealed. Therefore, in addition to depressive and manic states, psychosis may also be considered a manifestation resulting from additional impairments to neuronal plasticity. In the present manuscript, we hypothesize that moderate and more severe impairments to neuronal plasticity cause depressive and manic states, respectively, and that more serious impairments to neuronal plasticity cause psychosis. Many studies have suggested that impairments in neuronal plasticity contribute to schizophrenia and other mental disorders with psychotic features, and that the impairment of neuronal plasticity in schizophrenia is more severe than that in bipolar disorder. Therefore, we hypothesize more specifically that impairments in neuronal plasticity may be more severe in the order of the cases featuring psychosis, mania, and depression. This progression notably overlaps with the arrangement of schizophrenia, bipolar disorder, and depressive disorder in the DSM-5. Psychotic symptoms are thought to appear further towards the base of the psychopathological hierarchy than are manic or depressive symptoms. If impairments to neuronal plasticity contribute to this psychopathological hierarchy, as we contest that they do, our hypothesis may serve as a bridge between clinical psychopathology, diagnosis, and biological psychiatry.
Collapse
Affiliation(s)
- T Mizuno
- Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
| | - H Matsumoto
- Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan; Psychiatric Medical Center, Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui-City, Fukui 910-8526, Japan
| | - K Mita
- Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
| | - S Kogauchi
- Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
| | - Y Kiyono
- Biomedical Imaging Research Center, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
| | - H Kosaka
- Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
| | - N Omata
- Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan; Department of Nursing, Faculty of Health Science, Fukui Health Science University, 55 Egami-cho 13-1, Fukui-City, Fukui 910-3190, Japan.
| |
Collapse
|
65
|
Yamashita T, Hattori M, Nakada T, Hayashi T, Kamei K, Tatsuya T, Nagao Y, Mase T, Wada M, Mizuno T, Shimozuma K, Iwata H, Yamaguchi T. Abstract P4-11-02: Subjective and objective assessment of efficacy of frozen gloves and socks to prevent nab-paclitaxel-induced peripheral neuropathy in patients with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-11-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent side-effect of taxanes which play a central role in the treatment of breast cancer. CIPN can negatively influence long-term quality of life, warranting the development of effective prevention strategies. This study investigates the efficacy of frozen gloves and socks (FGS) in reducing the incidence and severity of nab-paclitaxel-induced peripheral neuropathy. Endpoints were evaluated using both clinician and patient reports.
Methods: This is a multicenter phase II single arm trial study of the effects of FGS for advanced or metastatic breast cancer patients receiving nab-paclitaxel (260 mg/m2) every 3 weeks. Patients wore FGS on their diseased side hand and foot for 60 min during infusion. The other side acted as the untreated control. CIPN was assessed using Patient Neurotoxicity Questionnaire (PNQ), PRO-CTCAE and CTCAE at baseline and every cycle of nab-paclitaxel. The primary endpoint was the incidence of CIPN assessed by PNQ (grade C or higher) after receipt of up to 4 cycles of nab-paclitaxel.
Results: Between September 2012 and January 2015, 50 patients from 16 sites were enrolled in this study. Of 50 patients, 27 (54%) received at least 4 cycles of nab-paclitaxel. There was a trend for the incidence of CIPN assessed by PNQ and PRO-CTCAE to be lower in the intervention side than in the control side, although this difference was not statistically significant. The incidence of CIPN assessed by CTCAE was significantly lower in the treated hand (Table).
Conclusions: Among breast cancer patients who received nab-paclitaxel, FGS produced favorable effects as detected by reduced clinician-reported CTCAE grades for CIPN, although the study did not detect differences in self-reported symptoms of CIPN using PRO-CTCAE or PNQ. Clinical trial information: UMIN000007907.
Difference according to the evaluation method of CIPN Hands (%) Feet (%) InterventionControlp*InterventionControlp*Patient-Reporting CIPNPNQ (grade C or higher)12190.3416160.63Patient-Reporting CIPNPRO-CTCAE Severity ≥ Moderate13180.0815160.56 Interference ≥ Somewhat7100.328100.32Clinician-Grading CIPNCTCAE (≥ Grade II)15190.0314131.0
*McNemar's test
Citation Format: Yamashita T, Hattori M, Nakada T, Hayashi T, Kamei K, Tatsuya T, Nagao Y, Mase T, Wada M, Mizuno T, Shimozuma K, Iwata H, Yamaguchi T. Subjective and objective assessment of efficacy of frozen gloves and socks to prevent nab-paclitaxel-induced peripheral neuropathy in patients with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-11-02.
Collapse
Affiliation(s)
- T Yamashita
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - M Hattori
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Nakada
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Hayashi
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - K Kamei
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Tatsuya
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Y Nagao
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Mase
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - M Wada
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Mizuno
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - K Shimozuma
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - H Iwata
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - T Yamaguchi
- Kanagawa Cancer Center, Yokohama, Kanagawa, Japan; Aichi Cnacer Center, Nagoya, Aichi, Japan; Gifu Municipal Hospital, Gifu, Japan; Nagoya Medical Center, Nagoya, Aichi, Japan; Ogaki Municipal Hospital, Ogaki, Gifu, Japan; Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan; Gifu Prefectural General Medical Center, Gifu, Japan; Ogaki Tokushukai Hospital, Ogaki, Gifu, Japan; Nishio City Hospital, Nishio, Aichi, Japan; Mie University Hospital, Tsu, Mie, Japan; Ritsumeikan University, Kusatsu, Shiga, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| |
Collapse
|
66
|
Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Ando M, Nagino M. Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. Br J Surg 2019; 106:626-635. [PMID: 30762874 DOI: 10.1002/bjs.11088] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 11/16/2018] [Accepted: 11/22/2018] [Indexed: 12/28/2022]
Abstract
BACKGROUND The indications for major hepatectomy for gallbladder cancer either with or without pancreatoduodenectomy remain controversial. The clinical value of these extended procedures was evaluated in this study. METHODS Patients who underwent major hepatectomy for gallbladder cancer between 1996 and 2016 were identified from a prospectively compiled database. Postoperative outcomes and overall survival were compared between patients undergoing major hepatectomy alone or combined with pancreatoduodenectomy (HPD). RESULTS Seventy-nine patients underwent major hepatectomy alone and 38 patients had HPD. The patients who underwent HPD were more likely to have T4 disease (P < 0·001), nodal metastasis (P = 0·015) and periaortic nodal metastasis (P = 0·006), but were less likely to receive adjuvant therapy (P = 0·006). HPD was associated with a high incidence of grade III or higher complications (P = 0·002) and death (P = 0·037). Overall survival was longer in patients who underwent major hepatectomy alone than in patients who underwent HPD (median survival time 32 versus 10 months; P < 0·001). In multivariable analysis, surgery in the early period (1996-2006) (P = 0·002), pathological T4 disease (P = 0·005) and distant metastasis (P < 0·001) were associated with shorter overall survival, and cystic duct tumour (P = 0·002) with longer overall survival. CONCLUSION Major hepatectomy alone for gallbladder cancer contributes to favourable overall survival with low morbidity and mortality, whereas HPD is associated with poor overall survival and high morbidity and mortality rates. HPD may eradicate locally spreading gallbladder cancer; however, the indication for the procedure is questioned from an oncological viewpoint.
Collapse
Affiliation(s)
- T Mizuno
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Y Yokoyama
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Igami
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - J Yamaguchi
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Onoe
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Watanabe
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Ando
- Data Coordinating Centre, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
67
|
Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Fukui M, Harada H, Mizuno T, Sakai Y, Takasu M, Kaneko MK, Kato Y. PMab-210: A Monoclonal Antibody Against Pig Podoplanin. Monoclon Antib Immunodiagn Immunother 2019; 38:30-36. [DOI: 10.1089/mab.2018.0038] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- Yoshikazu Furusawa
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
- New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan
- ZENOAQ RESOURCE CO., LTD., Koriyama, Japan
| | - Shinji Yamada
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Shunsuke Itai
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Japan
| | - Masato Sano
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Takuro Nakamura
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Miyuki Yanaka
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | | | - Hiroyuki Harada
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Japan
| | - Takuya Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Yusuke Sakai
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Masaki Takasu
- Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan
| | - Mika K. Kaneko
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Yukinari Kato
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
- New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan
| |
Collapse
|
68
|
Kato Y, Mizuno T, Yamada S, Nakamura T, Itai S, Yanaka M, Sano M, Kaneko MK. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin. Monoclon Antib Immunodiagn Immunother 2019; 37:218-223. [PMID: 30362926 PMCID: PMC6208159 DOI: 10.1089/mab.2018.0035] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Podoplanin (PDPN), a type I transmembrane sialoglycoprotein, is expressed in normal tissues, including lymphatic endothelial cells, pulmonary type I alveolar cells, and renal podocytes. The overexpression of PDPN in cancers is associated with hematogenous metastasis by interactions with the C-type lectin-like receptor 2 (CLEC-2). We have previously reported the development of a mouse monoclonal antibody (mAb) clone, PMab-38 (IgG1, kappa), against dog PDPN (dPDPN). PMab-38 reacted strongly with canine squamous cell carcinomas and melanomas, but not with lymphatic endothelial cells, indicating its cancer specificity. In this study, we developed and produced several mouse-canine chimeric antibodies originating from PMab-38. A mouse-canine chimeric antibody of subclass A (P38A) and a mouse-canine chimeric antibody of subclass B (P38B) were transiently produced using ExpiCHO-S cells. Core-fucose-deficient P38B (P38Bf) was developed using FUT8 knockout ExpiCHO-S cells. We compared the binding affinities, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC) of P38A, P38B, and P38Bf against Chinese hamster ovary (CHO)/dPDPN cells. Flow cytometry analysis showed that the KD of P38A, P38B, and P38Bf were 1.9 × 10−7, 5.2 × 10−9, and 6.5 × 10−9, respectively. Both P38B and P38Bf revealed high ADCC activities against CHO/dPDPN cells; P38Bf demonstrated significantly higher ADCC compared with P38B, especially at low concentrations. P38B and P38Bf exhibited higher CDC activities against CHO/dPDPN cells. Conversely, P38A did not exhibit any ADCC or CDC activity. In summary, P38Bf is a good candidate for antibody therapy against dPDPN-expressing canine cancers.
Collapse
Affiliation(s)
- Yukinari Kato
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan .,2 New Industry Creation Hatchery Center, Tohoku University , Sendai, Japan
| | - Takuya Mizuno
- 3 Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University , Yamaguchi, Japan
| | - Shinji Yamada
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan
| | - Takuro Nakamura
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan
| | - Shunsuke Itai
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan
| | - Miyuki Yanaka
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan
| | - Masato Sano
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan
| | - Mika K Kaneko
- 1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Japan
| |
Collapse
|
69
|
Ackermann M, Ajello M, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bellazzini R, Bissaldi E, Blandford RD, Bonino R, Bottacini E, Bregeon J, Bruel P, Buehler R, Burns E, Buson S, Cameron RA, Caputo R, Caraveo PA, Cavazzuti E, Chen S, Chiaro G, Ciprini S, Costantin D, Cuoco A, Cutini S, D'Ammando F, de la Torre Luque P, de Palma F, Desai A, Digel SW, Di Lalla N, Di Mauro M, Di Venere L, Fana Dirirsa F, Favuzzi C, Franckowiak A, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Giglietto N, Giordano F, Giroletti M, Green D, Grenier IA, Guillemot L, Guiriec S, Horan D, Jóhannesson G, Kuss M, Larsson S, Latronico L, Li J, Liodakis I, Longo F, Loparco F, Lubrano P, Magill JD, Maldera S, Malyshev D, Manfreda A, Mazziotta MN, Mereu I, Michelson PF, Mitthumsiri W, Mizuno T, Monzani ME, Morselli A, Moskalenko IV, Negro M, Nuss E, Orienti M, Orlando E, Palatiello M, Paliya VS, Paneque D, Persic M, Pesce-Rollins M, Petrosian V, Piron F, Porter TA, Principe G, Rainò S, Rando R, Razzano M, Razzaque S, Reimer A, Reimer O, Serini D, Sgrò C, Siskind EJ, Spandre G, Spinelli P, Suson DJ, Tajima H, Takahashi M, Thayer JB, Tibaldo L, Torres DF, Troja E, Venters TM, Vianello G, Wood K, Yassine M, Zaharijas G, Ammazzalorso S, Fornengo N, Regis M. Unresolved Gamma-Ray Sky through its Angular Power Spectrum. Phys Rev Lett 2018; 121:241101. [PMID: 30608723 DOI: 10.1103/physrevlett.121.241101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 10/11/2018] [Indexed: 06/09/2023]
Abstract
The gamma-ray sky has been observed with unprecedented accuracy in the last decade by the Fermi -large area telescope (LAT), allowing us to resolve and understand the high-energy Universe. The nature of the remaining unresolved emission [unresolved gamma-ray background (UGRB)] below the LAT source detection threshold can be uncovered by characterizing the amplitude and angular scale of the UGRB fluctuation field. This Letter presents a measurement of the UGRB autocorrelation angular power spectrum based on eight years of Fermi-LAT Pass 8 data products. The analysis is designed to be robust against contamination from resolved sources and noise systematics. The sensitivity to subthreshold sources is greatly enhanced with respect to previous measurements. We find evidence (with ∼3.7σ significance) that the scenario in which two classes of sources contribute to the UGRB signal is favored over a single class. A double power law with exponential cutoff can explain the anisotropy energy spectrum well, with photon indices of the two populations being 2.55±0.23 and 1.86±0.15.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - S Ammazzalorso
- Istituto Nazionale di Fisica Nucleare, Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università degli Studi di Torino, I-10125 Torino, Italy
| | - N Fornengo
- Istituto Nazionale di Fisica Nucleare, Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università degli Studi di Torino, I-10125 Torino, Italy
| | - M Regis
- Istituto Nazionale di Fisica Nucleare, Sezione di Torino, I-10125 Torino, Italy
- Dipartimento di Fisica, Università degli Studi di Torino, I-10125 Torino, Italy
| |
Collapse
|
70
|
Mizuno T, Horinouchi H, Watanabe S, Sato J, Morita R, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
71
|
Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Handa S, Mizuno T, Maeda K, Fukui M, Harada H, Kaneko MK, Kato Y. Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin. Monoclon Antib Immunodiagn Immunother 2018; 37:233-237. [DOI: 10.1089/mab.2018.0030] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- Yoshikazu Furusawa
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
- New Industry Creation Hatchery Center, Tohoku University, Sendai, Miyagi, Japan
- ZENOAQ RESOURCE CO., LTD., Koriyama, Fukushima, Japan
| | - Shinji Yamada
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Shunsuke Itai
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Masato Sano
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Takuro Nakamura
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Miyuki Yanaka
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Saori Handa
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Takuya Mizuno
- Laboratories of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Ken Maeda
- Laboratories of Veterinary Microbiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Masato Fukui
- ZENOAQ RESOURCE CO., LTD., Koriyama, Fukushima, Japan
| | - Hiroyuki Harada
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Mika K. Kaneko
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Yukinari Kato
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
- New Industry Creation Hatchery Center, Tohoku University, Sendai, Miyagi, Japan
| |
Collapse
|
72
|
Nagano M, Saito K, Kozuka Y, Shibusawa M, Imai N, Noro A, Kageyama Y, Mizuno T, Ogawa T, Katayama N. PD-L1 expression on circulating monocytes in patients with breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy427.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
73
|
Yamada S, Itai S, Furusawa Y, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Fukui M, Harada H, Mizuno T, Sakai Y, Ogasawara S, Murata T, Uchida H, Tahara H, Kaneko MK, Kato Y. Detection of Tiger Podoplanin Using the Anti-Cat Podoplanin Monoclonal Antibody PMab-52. Monoclon Antib Immunodiagn Immunother 2018; 37:224-228. [DOI: 10.1089/mab.2018.0033] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- Shinji Yamada
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Shunsuke Itai
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yoshikazu Furusawa
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
- New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan
- ZENOAQ RESOURCE CO., LTD., Koriyama, Japan
| | - Masato Sano
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Takuro Nakamura
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Miyuki Yanaka
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Saori Handa
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Kayo Hisamatsu
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Yoshimi Nakamura
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | | | - Hiroyuki Harada
- Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Takuya Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Yusuke Sakai
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Satoshi Ogasawara
- Department of Chemistry, Graduate School of Science, Chiba University, Inage, Japan
| | - Takeshi Murata
- Department of Chemistry, Graduate School of Science, Chiba University, Inage, Japan
| | - Hiroaki Uchida
- Project Division of Cancer Biomolecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Hideaki Tahara
- Project Division of Cancer Biomolecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Mika K. Kaneko
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Yukinari Kato
- Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan
- New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan
| |
Collapse
|
74
|
Ramsey LB, Mizuno T, Vinks AA, Margolis PA. Learning Health Systems as Facilitators of Precision Medicine. Clin Pharmacol Ther 2018; 101:359-367. [PMID: 27984650 DOI: 10.1002/cpt.594] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Revised: 12/05/2016] [Accepted: 12/07/2016] [Indexed: 12/24/2022]
Affiliation(s)
- L B Ramsey
- Division of Research in Patient Services, Pharmacy Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - T Mizuno
- Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - A A Vinks
- Division of Research in Patient Services, Pharmacy Research, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.,Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| | - P A Margolis
- James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
| |
Collapse
|
75
|
Matsui T, Kuroda H, Sugita Y, Koyama S, Nakanishi K, Arimura T, Mizuno T, Sakakura N, Sakao Y. P1.16-42 Indocyanine Green Intersegmental Visualization During Fluorescence Imaging of Thoracoscopic Anatomic Segmentectomy: A Novel Approach. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
76
|
Nakano Y, Wakabayashi H, Mukai K, Niwa T, Watanabe A, Ando H, Takashima H, Mizuno T, Waseda K, Amano T. P914Clinical impact of tricuspid annular plane systolic excursion, the index of right ventricular performance, to detect low cardiac output state. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Nakano
- Aichi Medical University, Nagakute, Japan
| | | | - K Mukai
- Aichi Medical University, Nagakute, Japan
| | - T Niwa
- Aichi Medical University, Nagakute, Japan
| | - A Watanabe
- Aichi Medical University, Nagakute, Japan
| | - H Ando
- Aichi Medical University, Nagakute, Japan
| | | | - T Mizuno
- Aichi Medical University, Nagakute, Japan
| | - K Waseda
- Aichi Medical University, Nagakute, Japan
| | - T Amano
- Aichi Medical University, Nagakute, Japan
| |
Collapse
|
77
|
Adachi T, Abe T, Mizuno T, Iida Y, Yamada T, Uchiyama S, Nishi M, Nagao T, Sakamoto K, Ito T, Fujimoto N, Kobayashi K, Okumura T, Yamada S. P3196Anorexia coexisted in frailty predicts 1-year prognosis in patients with heart failure: a multicenter prospective cohort study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- T Adachi
- Nagoya University Graduate School of Medicine, Department of Rehabilitation, Nagoya, Japan
| | - T Abe
- Aichi Medical University Hospital, Department of Rehabilitation, Nagakute, Japan
| | - T Mizuno
- Aichi Medical University Hospital, Department of Cardiology, Nagakute, Japan
| | - Y Iida
- Kainan Hospital, Department of Rehabilitation, Yatomi, Japan
| | - T Yamada
- Kainan Hospital, Department of Cardiology, Yatomi, Japan
| | - S Uchiyama
- New Tokyo hospital, Department of Rehabilitation, Matsudo, Japan
| | - M Nishi
- New Tokyo hospital, Department of Rehabilitation, Matsudo, Japan
| | - T Nagao
- Hoshi General Hospital, Department of Rehabilitation, Koriyama, Japan
| | - K Sakamoto
- Hoshi General Hospital, Department of Cardiology, Koriyama, Japan
| | - T Ito
- Mie University Hospital, Department of Rehabilitation, Tsu, Japan
| | - N Fujimoto
- Mie University Graduate School of Medicine, Department of Cardiology, Tsu, Japan
| | - K Kobayashi
- Nagoya University Hospital, Department of Rehabilitation, Nagoya, Japan
| | - T Okumura
- Nagoya University Hospital, Department of Cardiology, Nagoya, Japan
| | - S Yamada
- Nagoya University, Department of Health Sciences, Nagoya, Japan
| | | |
Collapse
|
78
|
Chauvin M, Florén HG, Friis M, Jackson M, Kamae T, Kataoka J, Kawano T, Kiss M, Mikhalev V, Mizuno T, Ohashi N, Stana T, Tajima H, Takahashi H, Uchida N, Pearce M. Publisher Correction: Shedding new light on the Crab with polarized X-rays. Sci Rep 2018; 8:7975. [PMID: 29773826 PMCID: PMC5958095 DOI: 10.1038/s41598-018-24853-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Collapse
Affiliation(s)
- M Chauvin
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden.,The Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, 106 91, Stockholm, Sweden
| | - H-G Florén
- Stockholm University, Department of Astronomy, 106 91, Stockholm, Sweden
| | - M Friis
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden.,The Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, 106 91, Stockholm, Sweden
| | - M Jackson
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden.,School of Physics and Astronomy, Cardiff University, Cardiff, CF24 3AA, UK
| | - T Kamae
- University of Tokyo, Department of Physics, Tokyo, 113-0033, Japan.,SLAC/KIPAC, Stanford University, 2575 Sand Hill Road, Menlo Park, CA, 94025, USA
| | - J Kataoka
- Research Institute for Science and Engineering, Waseda University, Tokyo, 169-8555, Japan
| | - T Kawano
- Hiroshima University, Department of Physical Science, Hiroshima, 739-8526, Japan
| | - M Kiss
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden.,The Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, 106 91, Stockholm, Sweden
| | - V Mikhalev
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden.,The Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, 106 91, Stockholm, Sweden
| | - T Mizuno
- Hiroshima University, Department of Physical Science, Hiroshima, 739-8526, Japan
| | - N Ohashi
- Hiroshima University, Department of Physical Science, Hiroshima, 739-8526, Japan
| | - T Stana
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden.,The Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, 106 91, Stockholm, Sweden
| | - H Tajima
- Institute for Space-Earth Environment Research, Nagoya University, Aichi, 464-8601, Japan
| | - H Takahashi
- Hiroshima University, Department of Physical Science, Hiroshima, 739-8526, Japan
| | - N Uchida
- Hiroshima University, Department of Physical Science, Hiroshima, 739-8526, Japan
| | - M Pearce
- KTH Royal Institute of Technology, Department of Physics, 106 91, Stockholm, Sweden. .,The Oskar Klein Centre for Cosmoparticle Physics, AlbaNova University Centre, 106 91, Stockholm, Sweden.
| |
Collapse
|
79
|
Okuno M, Goumard C, Mizuno T, Kopetz S, Omichi K, Tzeng CWD, Chun YS, Lee JE, Vauthey JN, Conrad C. Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases. Br J Surg 2018; 105:1200-1209. [PMID: 29664996 DOI: 10.1002/bjs.10822] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 12/11/2017] [Accepted: 12/13/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND Although perihepatic lymph node metastases (PLNMs) are known to be a poor prognosticator for patients with colorectal liver metastases (CRLMs), optimal management remains unclear. This study aimed to determine the risk factors for PLNMs, and the survival impact of their number and location in patients with resectable CRLMs. METHODS Data on patients with CRLM who underwent hepatectomy during 2003-2014 were analysed retrospectively. Recurrence-free (RFS) and overall (OS) survival were calculated according to presence, number and location of PLNMs. Risk factors for PLNM were evaluated by logistic regression analysis. RESULTS Of 1485 patients, 174 underwent lymphadenectomy, and 54 (31·0 per cent) had PLNM. Ten patients (5·7 per cent) who had lymphadenectomy and 176 (13·4 per cent) who did not underwent repeat hepatectomy. Survival of patients with PLNM was significantly poorer than that of patients without (RFS: 5·3 versus 13·8 months, P < 0·001; OS: 20·5 versus 71·3 months; P < 0·001). Median OS was significantly better in patients with para-aortic versus hepatoduodenal ligament PLNMs (58·2 versus 15·5 months; P = 0·011). Patients with three or more PLNMs had significantly worse median OS than those with one or two (16·3 versus 25·4 months; P = 0·039). The presence of primary tumour lymph node metastases (odds ratio 2·35; P = 0·037) and intrahepatic recurrence requiring repeat hepatectomy (odds ratio 5·61; P = 0·012) were significant risk factors for PLNM on multivariable analysis. CONCLUSION Patients undergoing repeat hepatectomy and those with primary tumour lymph node metastases are at significant risk of PLNM. Although PLNM is a poor prognostic factor independent of perihepatic lymph node station, patients with one or two PLNMs have a more favourable outcome than those with more PLNMs.
Collapse
Affiliation(s)
- M Okuno
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - C Goumard
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - T Mizuno
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - S Kopetz
- Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - K Omichi
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - C-W D Tzeng
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Y S Chun
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - J E Lee
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - J-N Vauthey
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - C Conrad
- Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
80
|
Ito A, Ebata T, Yokoyama Y, Igami T, Mizuno T, Yamaguchi J, Onoe S, Nagino M. Ethanol ablation for refractory bile leakage after complex hepatectomy. Br J Surg 2018; 105:1036-1043. [PMID: 29617036 DOI: 10.1002/bjs.10801] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 11/20/2017] [Accepted: 11/24/2017] [Indexed: 01/15/2023]
Abstract
BACKGROUND Only a few reports exist on the use of ethanol ablation for posthepatectomy bile leakage. The aim of this study was to assess the value of ethanol ablation in refractory bile leakage. METHODS Medical records of consecutive patients who underwent a first hepatobiliary resection with bilioenteric anastomosis between 2007 and 2016 were reviewed retrospectively, with special attention to bile leakage and ethanol ablation therapy. Bile leakage was graded as A/B1/B2 according to the International Study Group of Liver Surgery definition. Absolute ethanol was injected into the target bile duct during fistulography. RESULTS Of the 609 study patients, 237 (38·9 per cent) had bile leakage, including grade A in 33, grade B1 in 18 and grade B2 in 186. Left trisectionectomy was more often associated with grade B2 bile leakage than other types of hepatectomy (P < 0·001). Of 186 patients with grade B2 bile leakage, 31 underwent ethanol ablation therapy. Ethanol ablation was started a median of 34 (range 15-122) days after hepatectomy. The median number of treatments was 3 (1-7), and the total amount of ethanol used was 15 (3-71) ml. Complications related to ethanol ablation included transient fever (27 patients) and mild pain (13). Following ethanol ablation, bile leakage resolved in all patients and drains were removed. The median interval between the first ablation and drain removal was 28 (1-154) days. CONCLUSION Ethanol ablation is safe and effective, and may be a treatment option for refractory bile leakage.
Collapse
Affiliation(s)
- A Ito
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - Y Yokoyama
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - T Igami
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - T Mizuno
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - J Yamaguchi
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - S Onoe
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
| |
Collapse
|
81
|
Akiyama D, Nishimura T, Iizuka K, Mizuno T, Tsukiya T, Takewa Y, Ono M, Tatsumi E. Accurate Quantitative Evaluation of Aortic Insufficiency During LVAD Support by Thermodilution Analysis. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
82
|
Mizuno T, Tsukiya T, Takewa Y, Tatsumi E. Differences in Fibrin Metabolism Among the Species for Preclinical Large Animal Models for Cardiovascular Device. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
83
|
Iizuka K, Akiyama D, Takewa Y, Tsukiya T, Mizuno T, Nishimura T, Tatsumi E. Electrocardiogram-synchronized Rotational Speed Modulation System Can Reduce the Recirculation Due to Aortic Insufficiency in LVAD Support. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
84
|
Nemoto Y, Shosu K, Okuda M, Noguchi S, Mizuno T. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1. Vet Immunol Immunopathol 2018; 198:19-25. [PMID: 29571514 DOI: 10.1016/j.vetimm.2018.02.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Revised: 01/09/2018] [Accepted: 02/12/2018] [Indexed: 12/21/2022]
Abstract
Recent research has focused on immunotherapy, particularly with regard to cancer treatment. Programmed death-1 and programmed death ligand 1 (PD-1/PD-L1) pathway blockade is a central topic of the promising immunotherapy field. In veterinary medicine, observations of the PD-1/PD-L1 pathway, including the relationship between immune cells and diseases, have increased. In this study, monoclonal antibodies specific to canine PD-1 and PD-L1 were developed, and the antibodies against PD-1 and PD-L1 bind to PD-1 and PD-L1 overexpressing cells, respectively. Additionally, each antibody interfered with the interaction between PD-1 and PD-L1. The expression of PD-1 and PD-L1 was detected on activated T cells from canine peripheral blood mononuclear cells (PBMC), and, remarkably, was the first recorded instance of PD-L1 expression on canine immature dendritic cells. Production of IFN-γ by activated T cells increased significantly when incubated with anti-PD-1 antibody alone and with both anti-PD-1 and anti-PD-L1 antibodies, revealing the functional effects of the antibodies. The antibodies will be useful for research on immune systems and may be the first passive immunotherapy approach in canine cancer patients.
Collapse
Affiliation(s)
- Yuki Nemoto
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Kazuha Shosu
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Masaru Okuda
- Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan; Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Shunsuke Noguchi
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan; Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan
| | - Takuya Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan; Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, 1677-1 Yoshida, Yamaguchi, 753-8515, Japan.
| |
Collapse
|
85
|
Kobayashi A, Yusaku E, Ito H, Kawai H, Mizuno T, Kento F, Kimura S. Development of High Resolution Gamma-Detectors for PET. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201817009003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
86
|
Usui T, Sakurai M, Nishikawa S, Umata K, Nemoto Y, Haraguchi T, Itamoto K, Mizuno T, Noguchi S, Mori T, Iwai S, Nakagawa T, Yamawaki H, Ohama T, Sato K. Establishment of a dog primary prostate cancer organoid using the urine cancer stem cells. Cancer Sci 2017; 108:2383-2392. [PMID: 29024204 PMCID: PMC5715251 DOI: 10.1111/cas.13418] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2017] [Revised: 09/30/2017] [Accepted: 10/02/2017] [Indexed: 12/17/2022] Open
Abstract
Dog spontaneously develop prostate cancer (PC) like humans. Because most dogs with PC have a poor prognosis, they could be used as a translational model for advanced PC in humans. Stem cell‐derived 3‐D organoid culture could recapitulate organ structures and physiology. Using patient tissues, a human PC organoid culture system was established. Recent study has shown that urine cells also possess the characteristic of stem cells. However, urine cell‐derived PC organoids have never been produced. Therefore, we generated PC organoids using the dog urine samples. Urine organoids were successfully generated from each dog with PC. Each organoid showed cystic structures and resembled the epithelial structures of original tissues. Expression of an epithelial cell marker, E‐cadherin, and a myofibloblast marker, α‐SMA, was observed in the urine organoids. The organoids also expressed a basal cell marker, CK5, and a luminal cell marker, CK8. CD49f‐sorted basal cell organoids rapidly grew compared with CD24‐sorted luminal cell organoids. The population of CD44‐positive cells was the highest in both organoids and the original urine cells. Tumors were successfully formed with the injection of the organoids into immunodeficient mice. Treatment with a microtubule inhibitor, docetaxel, but not a cyclooxygenase inhibitor, piroxicam, and an mTOR inhibitor, rapamycin, decreased the cell viability of organoids. Treatment with a Hedgehog signal inhibitor, GANT61, increased the radiosensitivity in the organoids. These findings revealed that PC organoids using urine might become a useful tool for investigating the mechanisms of the pathogenesis and treatment of PC in dogs.
Collapse
Affiliation(s)
- Tatsuya Usui
- Laboratory of Veterinary Pharmacology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan
| | - Masashi Sakurai
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Shimpei Nishikawa
- Department of Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Koji Umata
- Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Yuki Nemoto
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Tomoya Haraguchi
- Department of Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Kazuhito Itamoto
- Department of Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Takuya Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Shunsuke Noguchi
- Laboratory of Veterinary Radiology, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Sakai, Osaka, Japan
| | - Takashi Mori
- Laboratory of Veterinary Clinical Oncology, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan
| | - Satomi Iwai
- Laboratory of Small Animal Surgery 2, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Takayuki Nakagawa
- Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan
| | - Hideyuki Yamawaki
- Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Kitasato University, Towada, Japan
| | - Takashi Ohama
- Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Koichi Sato
- Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| |
Collapse
|
87
|
Motomura H, Watanabe J, Togo S, Sumiyoshi I, Namba Y, Suina K, Mizuno T, Kadoya K, Iwai M, Nagaoka T, Sasaki S, Hayashi T, Uekusa T, Abe K, Urata Y, Sakurai F, Mizuguchi H, Kato S, Takahashi K. P1.03-006 Clinicopathological Features and Poor Outcome for ALK Inhibitors of Squamous Cell Lung Cancer with ALK-Rearrangement. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
88
|
Tsunoda A, Oda H, Mizuno T, Yamashita Y, Tamaru S, Saito K, Ishihara M, Nishimura Y, Nakatani K, Katayama N. Prospective analysis of the risk factors for cisplatin-induced acute kidney injury. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx676.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
89
|
Mizuno T, Arimura T, Kuroda H, Sakakura N, Yatabe Y, Sakao Y. Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
90
|
Hwang CC, Igase M, Sakurai M, Haraguchi T, Tani K, Itamoto K, Shimokawa T, Nakaichi M, Nemoto Y, Noguchi S, Coffey M, Okuda M, Mizuno T. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours. Vet Comp Oncol 2017; 16:229-238. [PMID: 29076241 DOI: 10.1111/vco.12361] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 09/17/2017] [Accepted: 09/18/2017] [Indexed: 12/26/2022]
Abstract
Oncolytic virotherapy is a novel treatment involving replication-competent virus in the elimination of cancer. We have previously reported the oncolytic effects of reovirus in various canine cancer cell lines. This study aims to establish the safety profile of reovirus in dogs with spontaneously occurring tumours and to determine a recommended dosing regimen. Nineteen dogs with various tumours, mostly of advanced stages, were treated with reovirus, ranging from 1.0 × 108 to 5.0 × 109 TCID50 given as intratumour injection (IT) or intravenous infusion (IV) daily for up to 5 consecutive days in 1 or multiple treatment cycles. Adverse events (AEs) were graded according to the Veterinary Cooperative Oncology Group- Common Terminology Criteria for Adverse Events (VCOG-CTCAE) v1.1 guidelines. Viral shedding, neutralizing anti-reovirus antibody (NARA) production and immunohistochemical (IHC) detection of reovirus protein in the tumours were also assessed. AE was not observed in most dogs and events were limited to Grade I or II fever, vomiting, diarrhoea and inflammation of the injected tumour. No infectious virus was shed and all dogs had elevated NARA levels post-treatment. Although IHC results were only available in 6 dogs, 4 were detected positive for reovirus protein. In conclusion, reovirus is well-tolerated and can be given safely to tumour-bearing dogs according to the dosing regimen used in this study without significant concerns of viral shedding. Reovirus is also potentially effective in various types of canine tumours.
Collapse
Affiliation(s)
- C C Hwang
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - M Igase
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - M Sakurai
- Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - T Haraguchi
- Laboratory of Small Animal Clinical Science (Surgical Division), Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - K Tani
- Laboratory of Veterinary Surgery, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - K Itamoto
- Laboratory of Small Animal Clinical Science (Surgical Division), Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - T Shimokawa
- Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - M Nakaichi
- Laboratory of Veterinary Radiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Y Nemoto
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - S Noguchi
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - M Coffey
- Oncolytics Biotech Inc, Calgary, Canada
| | - M Okuda
- Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.,Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| | - T Mizuno
- Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.,Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan
| |
Collapse
|
91
|
Konno T, Yoshida K, Mizuta I, Mizuno T, Kawarai T, Tada M, Nozaki H, Ikeda SI, Onodera O, Wszolek ZK, Ikeuchi T. Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation. Eur J Neurol 2017; 25:142-147. [PMID: 28921817 DOI: 10.1111/ene.13464] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Accepted: 09/07/2017] [Indexed: 02/02/2023]
Abstract
BACKGROUND AND PURPOSE To establish and validate diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) due to colony-stimulating factor 1 receptor (CSF1R) mutation. METHODS We developed diagnostic criteria for ALSP based on a recent analysis of the clinical characteristics of ALSP. These criteria provide 'probable' and 'possible' designations for patients who do not have a genetic diagnosis. To verify its sensitivity and specificity, we retrospectively applied our criteria to 83 ALSP cases who had CSF1R mutations (24 of these were analyzed at our institutions and the others were identified from the literature), 53 cases who had CSF1R mutation-negative leukoencephalopathies and 32 cases who had cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) with NOTCH3 mutations. RESULTS Among the CSF1R mutation-positive cases, 50 cases (60%) were diagnosed as 'probable' and 32 (39%) were diagnosed as 'possible,' leading to a sensitivity of 99% if calculated as a ratio of the combined number of cases who fulfilled 'probable' or 'possible' to the total number of cases. With regard to specificity, 22 cases (42%) with mutation-negative leukoencephalopathies and 28 (88%) with CADASIL were correctly excluded using these criteria. CONCLUSIONS These diagnostic criteria are very sensitive for diagnosing ALSP with sufficient specificity for differentiation from CADASIL and moderate specificity for other leukoencephalopathies. Our results suggest that these criteria are useful for the clinical diagnosis of ALSP.
Collapse
Affiliation(s)
- T Konno
- Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.,Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
| | - K Yoshida
- Department of Brain Disease Research, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - I Mizuta
- Department of Neurology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan
| | - T Mizuno
- Department of Neurology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan
| | - T Kawarai
- Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - M Tada
- Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
| | - H Nozaki
- Department of Medical Technology, School of Health Sciences Faculty of Medicine, Niigata University, Niigata, Japan
| | - S-I Ikeda
- Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - O Onodera
- Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
| | - Z K Wszolek
- Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
| | - T Ikeuchi
- Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan
| |
Collapse
|
92
|
Okada Y, Ochi H, Fujii C, Hashi Y, Hamatani M, Ashida S, Kawamura K, Kusaka H, Nakagawa M, Mizuno T, Takahashi R, Kondo T. Dual engagement of TLR4 and CD40 on B cells as a key feature of recovery from relapse. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
93
|
Azuma Y, Tokuda T, Kushimura Y, Yamamoto I, Yoshida H, Mizuta I, Ueyama M, Nagai Y, Nakagawa M, Mizuno T, Yamaguchi M. The search for genes that modulate FUS-mediated phenotypes by Drosophila amyotrophic lateral sclerosis model. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
94
|
Kuwahara H, Song J, Shimoura T, Yoshida-Tanaka K, Mizuno T, Mochizuki T, Nishina K, Nagata T, Kusuhara H, Yokota T. Heteroduplex oligonucleotide as a platform technology to modulate blood-brain barrier function in vivo. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
95
|
Yoshida T, Mizuta I, Rei Y, Jun M, Mieno M, Kubota M, Sasaki M, Matsui M, Saitsu H, Takanashi J, Kurosawa K, Yamamoto T, Inoue K, Mizuno T, Osaka H. Revised guidelines for diagnosing Alexander disease and their validity. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
96
|
Kushimura Y, Tokuda T, Azuma Y, Yamamoto I, Yoshida H, Mizuta I, Ueyama M, Nagai Y, Nakagawa M, Mizuno T, Yamaguchi M. Loss of function mutant of ter94, Drosophila VCP, partially enhanced motor neuron degeneration induced by knockdown of TBPH, Drosophila TDP-43. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
97
|
Kuriyama N, Ihara M, Koyama T, Mizuno T, Ozaki E, Kondo M, Tokuda T, Tamura A, Kazuo T, Nakagawa M, Watanabe Y. Vasoactive mid-regional pro-adrenomedullin is associated with cognitive decline accompa-nying deep white matter lesions in the brain: A longitudinal brain MRI study. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
98
|
Yasuda R, Yoshida T, Mizuta I, Mizuno T. Effects of GFAP promoter polymorphism on age at onset of Alexander disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
99
|
Watanabe A, Koizumi T, Mukai M, Mizuta I, Ohara T, Mizuno T. Intracranial artery stenosis in Japanese CADASIL patients. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
100
|
Niwa F, Kondo M, Ishii R, Yamada T, Yamaguchi T, Mizuno T, Nakagawa M. The survey about cognitive decline in the presenile residents in Tango, Kyoto. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|